Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probenecid effect on JNJ-64041575 pharmacokinetics in healthy adults
NCT03105986Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lumicitabine (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration of JNJ-63549109 at 168 hours, Area Under Plasma Concentration Time Curve From Time Zero to the Last Quantifiable of JNJ-63549109 at 168 hours and 1 more. Started Apr 2017; status: completed.
02
Drugs
lumicitabine
Beyond the preview
Go deeper on NCT03105986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03105986.